The second-stage regression can then be expected to yield an intercept
that approximates [[beta].
Blood Systems, based on the Helinx technology, are designed to inactivate viruses, bacteria and other pathogens.
Haynes and Klehr recount all the major espionage cases described by the intercepts
A vehicle intercept
is not a moving road block, and suspect cars traveling more than 10 miles per hour are not considered viable intercept
Platelet System is paving the way in our comprehensive approach to the inactivation of pathogens in all three transfusion blood components.
Based on our extensive experience with INTERCEPT
platelets, we expect a simple and successful implementation of the INTERCEPT
The company expects that, with the purchase of the new INTERCEPT
illuminators, over 40 Russian centers will be capable of producing INTERCEPT
platelets and plasma.
We look forward to working with Ilex to bring INTERCEPT
pathogen inactivation to both South Africa and Israel.
Cerus previously received CE mark approval for the INTERCEPT
platelet and plasma systems, which allows Cerus to sell the systems in the European Union.
We believe that CSL, as one of the largest biopharmaceutical companies in the world, is an ideal partner to bring INTERCEPT
to these new markets," said Claes Glassell, president and chief executive officer of Cerus Corporation.
A control arm (72 patients) provided data to compare with the data generated for INTERCEPT
platelets (44 patients).
Cerus Corporation (NASDAQ:CERS) announced results of 22 abstracts presenting experiences with the INTERCEPT
Blood System for platelets, plasma and red blood cells during the XXXIst International Congress of the International Society for Blood Transfusion in Berlin, Germany held from June 26 to July 1.
Cerus Corporation (NASDAQ:CERS) announced today that investigators from blood centers in Sweden, Belgium, France and Slovenia will present their experience with the INTERCEPT
Blood System for platelets and plasma during a leading international transfusion safety meeting, the XIIth International Haemovigilance Seminar taking place in Dubrovnik, Croatia from February 17 to 19.
Cerus Corporation (NASDAQ:CERS) announced today that the Swiss regulatory body, Swissmedic, has approved the use of platelet components treated with Cerus' INTERCEPT
Results from 10 Studies Highlight the INTERCEPT
Blood System's Ability to Improve the Safety of Donated Blood Components, Including Platelets, Plasma and Red Blood Cells